It has been demonstrated that T cell responses could be stimulated by targeting this pathway with immune checkpoint inhibitors (iCPIs), which block the interaction of PD-1 with its ligands thereby overcoming the intrinsic resistance to immune surveillance by mounting anti-tumor immune responses [6,7,8]. This evidence concerns the gene PDCD1 and neoplasm.